Top Markets
#1 Seeker Seeker +18.80%
#2 EXOD EXOD +9.04%
#3 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +7.47%
#4 Arowana Arowana +5.88%
#5 MetaDAO MetaDAO +4.67%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +4.02%
#7 Mina Protocol Mina Protocol +3.88%
#8 Pons Pons +3.00%
#9 Solstice Solstice +2.88%
#10 Official Trump Official Trump +2.75%
Coin of the day
Seeker Seeker
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Rang in Aktien #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Aktienkurs
$64.97
Zuletzt synchronisiert: 2024-05-20
Marktkapitalisierung
$1.97B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Alpine Immune Sciences, Inc. (ALPN)

Kategorie

Healthcare
P/S-Verhältnis für Alpine Immune Sciences, Inc. (ALPN)
P/S-Verhältnis zum August 2026 TTM: 75.70
Laut den neuesten Finanzberichten und dem Aktienkurs von Alpine Immune Sciences, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 75.70. Am Ende des Jahres 2022 lag das P/S-Verhältnis bei 8.17.
P/S-Verlauf für Alpine Immune Sciences, Inc. von 2012 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
2026 (TTM) 75.70 367.56%
2023 16.19 98.02%
2022 8.17 -45.69%
2021 15.05 -46.46%
2020 28.11 -30.62%
2019 40.52 -43.96%
2018 72.29 72.38%
2017 41.94 256.51%
2016 11.76 -92.02%
2015 147.42 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -86.57%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -86.62%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -96.10%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -85.10%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH